• 1
    Myron Kauffman H, McBride MA, Cherikh WS, Spain PC, Marks WH, Roza AM. Transplant tumor registry: donor related malignancies. Transplantation 2002; 74: 358362.
  • 2
    Buell JF, Trofe J, Sethuraman G et al. Donors with central nervous system malignancies: are they truly safe Transplantation 2003; 76: 340343.
  • 3
    Kauffman HM, McBride MA, Cherikh WS, Spain PC, Delmonico FL. Transplant tumor registry: donors with central nervous system tumors1. Transplantation 2002; 73: 579582.
  • 4
    Chui AK, Herbertt K, Wang LS et al. Risk of tumor transmission in transplantation from donors with primary brain tumors: an Australian and New Zealand registry report. Transplant Proc 1999; 31: 12661267.
  • 5
    Holland EC. Gliomagenesis: genetic alterations and mouse models. Nat Rev Genet 2001; 2: 120–129.
  • 6
    Penn I. Primary kidney tumors before and after renal transplantation. Transplantation 1995; 59: 480485.
  • 7
    Rosen PR, Groshen S, Saigo PE, Kinne DW, Hellman S. A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma. J Clin Oncol 1989; 7: 355366.
  • 8
    Merrill RM, Henson DE, Ries LA. Conditional survival estimates in 34,963 patients with invasive carcinoma of the colon. Dis Colon Rectum 1998; 41: 10971106.
  • 9
    Kasiske BL, Cangro CB, Hariharan S et al. The evaluation of renal transplantation candidates: clinical practice guidelines. Am J Transplant 2002; 2 (Suppl 2): 195.
  • 10
    Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693699.
  • 11
    Sandgren EP, Quaife CJ, Pinkert CA, Palmiter RD, Brinster RL. Oncogene-induced liver neoplasia in transgenic mice. Oncogene 1989; 4: 715724.
  • 12
    Finkelstein SD, Marsh W, Demetris AJ et al. Microdissection-based allelotyping discriminates de novo tumor from intrahepatic spread in hepatocellular carcinoma. Hepatology 2003; 37: 871879.
  • 13
    Yao FY, Bass NM, Nikolai B et al. Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl 2002; 8: 873883.
  • 14
    Marsh JW, Dvorchik I, Bonham CA, Iwatsuki S. Is the pathologic TNM staging system for patients with hepatoma predictive of outcome Cancer 2000; 88: 538–543.
  • 15
    Yao FY, Ferrell L, Bass NM, Bacchetti P, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl 2002; 8: 765774.
  • 16
    Henschke CI, McCauley DI, Yankelevitz DF et al. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet 1999; 354: 99105.
  • 17
    Anyanwu AC, Townsend ER, Banner NR, Burke M, Khaghani A, Yacoub MH. Primary lung carcinoma after heart or lung transplantation: management and outcome. J Thorac Cardiovasc Surg 2002; 124: 11901197.
  • 18
    Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003; 348: 16811691.
  • 19
    Martinez JC, Otley CC, Stasko T et al. Defining the clinical course of metastatic skin cancer in organ transplant recipients: a multicenter collaborative study. Arch Dermatol 2003; 139: 301306.
  • 20
    Veness MJ, Quinn DI, Ong CS et al. Aggressive cutaneous malignancies following cardiothoracic transplantation: the Australian experience. Cancer 1999; 85: 17581764.
  • 21
    Bouwes Bavinck JN, Feltkamp M, Struijk L, Ter Schegget J. Human papillomavirus infection and skin cancer risk in organ transplant recipients. J Investig Dermatol Symp Proc 2001; 6: 207211.
  • 22
    Harwood CA, Surentheran T, McGregor JM et al. Human papillomavirus infection and non-melanoma skin cancer in immunosuppressed and immunocompetent individuals. J Med Virol 2000; 61: 289297.
  • 23
    Boxman IL, Berkhout RJ, Mulder LH et al. Detection of human papillomavirus DNA in plucked hairs from renal transplant recipients and healthy volunteers. J Invest Dermatol 1997; 108: 712715.
  • 24
    Harris NL, Swerdlow SH, Frizzera G, Knowles DM. Post-transplant lymphoproliferative disorders. In: JaffeeES, HarrisNL, SteinH, VardimanJW (eds). Pathology and Genetics of Tumous of the Hematopoietic and Lymphoid Tissues. Lyon : IARC Press, 2001: 264.
  • 25
    Hanto DW. Classification of Epstein-Barr virus-associated posttransplant lymphoproliferative diseases: implications for understanding their pathogenesis and developing rational treatment strategies. Annu Rev Med 1995; 46: 381394.
  • 26
    Cockfield SM. Identifying the patient at risk for post-transplant lymphoproliferative disorder. Transpl Infect Dis 2001; 3: 7078.
  • 27
    Swinnen LJ. Organ transplant-related lymphoma. Curr Treat Options Oncol 2001; 2: 301308.
  • 28
    Gross TG. Low-dose chemotherapy for children with post-transplant lymphoproliferative disease. Recent Results Cancer Res 2002; 159: 96103.
  • 29
    Garnier JL, Stevenson G, Blanc-Brunat N et al. Treatment of post-transplant lymphomas with anti-B-cell monoclonal antibodies. Recent Results Cancer Res 2002; 159: 113122.
  • 30
    Herndier B, Ganem D. The biology of Kaposi's sarcoma. Cancer Treat Res 2001; 104: 89126.
  • 31
    Walter EA, Greenberg PD, Gilbert MJ et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995; 333: 10381044.
  • 32
    Luan FL, Hojo M, Maluccio M, Yamaji K, Suthanthiran M. Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation 2002; 73: 15651572.
  • 33
    Guba M, Von Breitenbuch P, Steinbauer M et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8: 128135.